-
Ocrevus shows higher efficacy than Rebif on NEDA in RRMS patients, a recent analysis shows
- April 2, 2018
- Posted by: PharmaScroll
- Category:
No Comments -
FLX-787 in Multiple Sclerosis displays positive Phase 2 Topline results
- March 28, 2018
- Posted by: PharmaScroll
- Category:
-
Successful results for Multiple Sclerosis MAb GNbAC1 announced by GeNeuro and Servier in Phase 2b CHANGE-MS Study
- March 27, 2018
- Posted by: PharmaScroll
- Category:
-
Secondary Progressive MS – Pharmascroll Report predicts increase in market activity in next 5-10 years
- March 26, 2018
- Posted by: PharmaScroll
- Category:
Expected launch of Siponimod and a strong pipeline in SPMS indicates a strong SPMS focus. SPMS- Detailed overview provides an overview of SPMS in detail, highlights the SPMS epidemiology, elaborates on the drugs prescribed and expected to be prescribed along with the sales and patient numbers forecast.
-
Siponimod significantly improves patient outcomes in SPMS, as per latest study
- March 23, 2018
- Posted by: PharmaScroll
- Category:
- 1
- 2